Header Logo

Prudence

Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Inzaule SC, Kroeze S, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Steegen K, Nankya I, Boender TS, Ondoa P, Sigaloff KCE, de Wit TFR, Hamers RL. Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multi-country longitudinal cohort analysis. AIDS. 2022 May 24. PMID: 35608116.
      Citations: 6     Fields:    Translation:Humans
    2. Picton ACP, Paximadis M, Koor GW, Bharuthram A, Shalekoff S, Lassauniere R, Ive P, Tiemessen CT. Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers. Front Immunol. 2021; 12:781263. PMID: 34987508; PMCID: PMC8720782.
      Citations: 1     Fields:    Translation:HumansCells
    3. Kendall MA, Lalloo U, Fletcher CV, Wu X, Podany AT, Cardoso SW, Ive P, Benson CA. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clin Infect Dis. 2021 08 16; 73(4):706-715. PMID: 34398956; PMCID: PMC8366816.
      Citations: 5     Fields:    Translation:HumansCells
    4. Nel J, Ive P, Nel C. Giant bacillary angiomatosis. South Afr J HIV Med. 2021; 22(1):1257. PMID: 34394972; PMCID: PMC8335775.
      Citations:    
    5. Mehta R, Ive P, Evans D, Menezes CN. Treatment outcomes among patients admitted to hospital with antiretroviral and/or antituberculosis drug-induced liver injury. S Afr Med J. 2021 Apr 30; 111(5):474-481. PMID: 34852891.
      Citations: 1     Fields:    Translation:Humans
    6. Richards L, Spencer DC, Nel JS, Ive P. Infectious disease consultations at a South African academic hospital: A 6-month assessment of inpatient consultations. S Afr J Infect Dis. 2020; 35(1):169. PMID: 34485477; PMCID: PMC8378114.
      Citations: 1     
    7. Inzaule SC, Bertagnolio S, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, Ondoa P, Sigaloff KCE, Rinke de Wit TF, Hamers RL. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020 08 01; 34(10):1559-1566. PMID: 32675566.
      Citations: 7     Fields:    Translation:Humans
    8. Govender NP, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D, Rabie H, Wilson D, Black J, Boulware D, Boyles T, Chiller T, Dawood H, Dlamini S, Harrison TS, Ive P, Jarvis J, Karstaedt A, Madua MC, Menezes C, Moosa MS, Motlekar Z, Shroufi A, Stacey SL, Tsitsi M, van Cutsem G, Variava E, Venter M, Wake R. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019; 20(1):1030. PMID: 32201629; PMCID: PMC7081625.
      Citations: 41     
    9. Inzaule SC, Kityo CM, Siwale M, Akanmu AS, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, Ondoa P, Sigaloff KCE, Naniche D, Rinke de Wit TF, Hamers RL. Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance. Sci Rep. 2018 10 25; 8(1):15751. PMID: 30361640; PMCID: PMC6202366.
      Citations: 6     Fields:    Translation:Humans
    10. Steinhaus N, Al-Talib M, Ive P, Boyles T, Bamford C, Davies MA, Mendelson M, Wasserman S. The management and outcomes of Staphylococcus aureus bacteraemia at a South African referral hospital: A prospective observational study. Int J Infect Dis. 2018 Aug; 73:78-84. PMID: 29908251.
      Citations: 8     Fields:    Translation:Humans
    11. Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, de Pundert ME, Sigaloff KCE, Reiss P, Wit FWNM, Rinke de Wit TF, Hamers RL. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. AIDS. 2018 05 15; 32(8):1043-1051. PMID: 29547445.
      Citations: 27     Fields:    Translation:Humans
    12. Evans D, Hirasen K, Berhanu R, Malete G, Ive P, Spencer D, Badal-Faesen S, Sanne IM, Fox MP. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10. PMID: 29636106; PMCID: PMC5891887.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    13. Rohr JK, Ive P, Horsburgh CR, Berhanu R, Hoffmann CJ, Wood R, Boulle A, Giddy J, Prozesky H, Vinikoor M, Mwanza MW, Wandeler G, Davies MA, Fox MP. Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. J Acquir Immune Defic Syndr. 2018 04 01; 77(4):413-416. PMID: 29206723; PMCID: PMC5825249.
      Citations: 1     Fields:    Translation:Humans
    14. Nel JS, Ive P, Lippincott CK. Reply to Gupta-Wright et al. Clin Infect Dis. 2018 01 06; 66(1):159. PMID: 29020258.
      Citations:    Fields:    Translation:Cells
    15. Nel JS, Lippincott CK, Berhanu R, Spencer DC, Sanne IM, Ive P. Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review. Clin Infect Dis. 2017 10 01; 65(7):1226-1228. PMID: 28575238.
      Citations: 9     Fields:    Translation:HumansCells
    16. Rohr JK, Ive P, Horsburgh CR, Berhanu R, Shearer K, Maskew M, Long L, Sanne I, Bassett J, Ebrahim O, Fox MP. Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa. J Int AIDS Soc. 2016; 19(1):20987. PMID: 27677395; PMCID: PMC5039239.
      Citations: 15     Fields:    
    17. Budgell EP, Evans D, Schnippel K, Ive P, Long L, Rosen S. Outcomes of treatment of drug-susceptible tuberculosis at public sector primary healthcare clinics in Johannesburg, South Africa: A retrospective cohort study. S Afr Med J. 2016 Sep 05; 106(10):1002-1009. PMID: 27725021.
      Citations: 11     Fields:    
    18. Rohr JK, Ive P, Horsburgh CR, Berhanu R, Shearer K, Maskew M, Long L, Sanne I, Bassett J, Ebrahim O, Fox MP. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469. PMID: 27548695; PMCID: PMC4993510.
      Citations: 29     Fields:    Translation:HumansCells
    19. Fox MP, Berhanu R, Steegen K, Firnhaber C, Ive P, Spencer D, Mashamaite S, Sheik S, Jonker I, Howell P, Long L, Evans D. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016 09; 21(9):1131-7. PMID: 27383454.
      Citations: 31     Fields:    Translation:HumansCells
    20. Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA. Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PLoS One. 2016; 11(7):e0158262. PMID: 27367521; PMCID: PMC4930205.
      Citations: 14     Fields:    Translation:HumansCells
    21. Thiébaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, Speck RF, D'Offizi G, Casari S, Commenges D, Foulkes S, Natarajan V, Croughs T, Delfraissy JF, Tambussi G, Levy Y, Lederman MM. Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. Clin Infect Dis. 2016 May 01; 62(9):1178-1185. PMID: 26908786; PMCID: PMC4826452.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    22. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747. PMID: 25795076.
      Citations: 105     Fields:    Translation:HumansCTClinical Trials
    23. Crump JA, Wu X, Kendall MA, Ive PD, Kumwenda JJ, Grinsztejn B, Jentsch U, Swindells S. Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study. BMC Infect Dis. 2015 Jan 13; 15:12. PMID: 25582793; PMCID: PMC4297427.
      Citations: 10     Fields:    Translation:HumansCells
    24. Ive P, Mendelson M, Dlamini S. Fever, sore throat and myalgia. S Afr Med J. 2014 Dec 16; 105(2):157. PMID: 26242513.
      Citations:    Fields:    
    25. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J, Adult AIDS Clinical Trials Group A5221 Study Team. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8. PMID: 24226057; PMCID: PMC3943693.
      Citations: 43     Fields:    Translation:Humans
    26. Cooper DA, Heera J, Ive P, Botes M, Dejesus E, Burnside R, Clumeck N, Walmsley S, Lazzarin A, Mukwaya G, Saag M, van Der Ryst E. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. AIDS. 2014 Mar 13; 28(5):717-25. PMID: 24983542; PMCID: PMC3940293.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    27. Dawany N, Showe LC, Kossenkov AV, Chang C, Ive P, Conradie F, Stevens W, Sanne I, Azzoni L, Montaner LJ. Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925. PMID: 24587128; PMCID: PMC3934945.
      Citations: 20     Fields:    Translation:HumansCells
    28. Ive P, MacLeod W, Mkumla N, Orrell C, Jentsch U, Wallis CL, Stevens W, Wood R, Sanne I, Bhattacharya D. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900. PMID: 24324573; PMCID: PMC3855615.
      Citations: 8     Fields:    Translation:HumansCells
    29. Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794. PMID: 24256692; PMCID: PMC3835788.
      Citations: 15     Fields:    Translation:Humans
    30. Hamers RL, Zaaijer HL, Wallis CL, Siwale M, Ive P, Botes ME, Sigaloff KC, Hoepelman AI, Stevens WS, Rinke de Wit TF, PharmAccess African Studies to Evaluate Resistance (PASER). HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):174-82. PMID: 23892239.
      Citations: 33     Fields:    Translation:HumansCells
    31. Vardhanabhuti S, Acosta EP, Ribaudo HJ, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan ES, Hitti J, Hong F, McMahon D, Haas DW, A5207 ACTG Study Team. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. J Infect Dis. 2013 Aug 15; 208(4):662-71. PMID: 23687222; PMCID: PMC3719905.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    32. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F, Adult AIDS Clinical Trials Group A5221 Study Team. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. PMID: 23592830; PMCID: PMC3719885.
      Citations: 31     Fields:    Translation:Humans
    33. Menezes CN, Duarte R, Dickens C, Dix-Peek T, Van Amsterdam D, John MA, Ive P, Maskew M, Macphail P, Fox MP, Raal F, Sanne I, Crowther NJ. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25. PMID: 23036096.
      Citations: 2     Fields:    Translation:HumansCells
    34. Sigaloff KC, Hamers RL, Menke J, Labib M, Siwale M, Ive P, Botes ME, Kityo C, Mandaliya K, Wellington M, Osibogun A, Geskus RB, Stevens WS, van Vugt M, Rinke de Wit TF, PharmAccess African Studies to Evaluate Resistance. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012 May; 54 Suppl 4:S294-9. PMID: 22544190.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    35. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R, PharmAccess African Studies to Evaluate Resistance (PASER). Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012 Jun; 54(11):1660-9. PMID: 22474222.
      Citations: 92     Fields:    Translation:HumansCells
    36. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, Rinke de Wit TF, PharmAccess African Studies to Evaluate Resistance (PASER). Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012 Jun; 205(11):1739-44. PMID: 22448003.
      Citations: 41     Fields:    Translation:HumansCells
    37. Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, Orrell C, Zeinecker J, Sanne I, Wood R, McIntyre J, Stevens W, CIPRA-SA project 1 study team. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20. PMID: 22293461; PMCID: PMC3600633.
      Citations: 14     Fields:    Translation:HumansCells
    38. Conradie F, Foulkes AS, Ive P, Yin X, Roussos K, Glencross DK, Lawrie D, Stevens W, Montaner LJ, Sanne I, Azzoni L. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18. PMID: 21826013; PMCID: PMC3196770.
      Citations: 28     Fields:    Translation:HumansCells
    39. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Wit FW, van Vugt M, Stevens WS, de Wit TF, PharmAccess African Studies to Evaluate Resistance (PASER) Investigators. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012 Apr; 12(4):307-17. PMID: 22036233.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    40. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91. PMID: 22010914; PMCID: PMC3327101.
      Citations: 272     Fields:    Translation:HumansCells
    41. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF, PharmAccess African Studies to Evaluate Resistance (PASER). Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):23-31. PMID: 21694603.
      Citations: 107     Fields:    Translation:HumansCellsCTClinical Trials
    42. Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, Maotoe T, Fox M. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011 Aug 24; 25(13):1603-9. PMID: 21646902; PMCID: PMC3586413.
      Citations: 49     Fields:    Translation:Humans
    43. Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34. PMID: 21685540; PMCID: PMC3145153.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    44. Fox MP, Sanne IM, Conradie F, Zeinecker J, Orrell C, Ive P, Rassool M, Dehlinger M, van der Horst C, McIntyre J, Wood R. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50. PMID: 20613459; PMCID: PMC2914833.
      Citations: 23     Fields:    Translation:Humans
    45. Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J, Cornell M, Heiberg C, Ingram C, Panchia R, Rassool M, Gonin R, Stevens W, Truter H, Dehlinger M, van der Horst C, McIntyre J, Wood R, CIPRA-SA Study Team. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40. PMID: 20557927; PMCID: PMC3145152.
      Citations: 112     Fields:    Translation:HumansCells
    46. Robertson K, Liner J, Hakim J, Sankalé JL, Grant I, Letendre S, Clifford D, Diop AG, Jaye A, Kanmogne G, Njamnshi A, Langford TD, Weyessa TG, Wood C, Banda M, Hosseinipour M, Sacktor N, Nakasuja N, Bangirana P, Paul R, Joska J, Wong J, Boivin M, Holding P, Kammerer B, Van Rie A, Ive P, Nath A, Lawler K, Adebamowo C, Royal W, Joseph J, NeuroAIDS in Africa Conference Participants. NeuroAIDS in Africa. J Neurovirol. 2010 May; 16(3):189-202. PMID: 20500018; PMCID: PMC3549534.
      Citations: 29     Fields:    Translation:Humans
    47. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6. PMID: 19838128.
      Citations: 53     Fields:    Translation:Humans
    48. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15; 201(6):803-13. PMID: 20151839.
      Citations: 101     Fields:    Translation:HumansCellsCTClinical Trials
    49. Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, Rubel D, Boulmé R, Eron J, Sanne I. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15. PMID: 19279444; PMCID: PMC2848384.
      Citations: 28     Fields:    Translation:Humans
    50. Gathe JC, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004 Jul 23; 18(11):1529-37. PMID: 15238771.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    Ive's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (181)
    Explore
    _
    Co-Authors (19)
    Explore
    _
    Similar People (60)
    Explore
    _